TEVA Admits to Mislabeling Generic Yaz
Written By: Rheingold, Giuffra, Ruffo & Plotkin LLP
Drug manufacturer TEVA admitted in a court proceeding Wednesday that some
of the information on it's label of Gianvi, the generic version of
Bayer's drug YAZ, was false.
TEVA's label of Gianvi in the US falsely claimed it contained Bayer's technology that extended the shelf life of it's drug. TEVA has provided the corrected information to the FDA and has already changed it's label on their website.
YAZ, Yasmin, and Ocella have been linked to an increased rate of blood clots, strokes, and gallbladder problems. If you have been injured by one of these drugs or their generic counterparts Contact Rheingold, Giuffra, Ruffo & Plotkin LLP for a free consultation.
Posted By
Rheingold, Giuffra, Ruffo & Plotkin LLP
Categories:
TEVA's label of Gianvi in the US falsely claimed it contained Bayer's technology that extended the shelf life of it's drug. TEVA has provided the corrected information to the FDA and has already changed it's label on their website.
YAZ, Yasmin, and Ocella have been linked to an increased rate of blood clots, strokes, and gallbladder problems. If you have been injured by one of these drugs or their generic counterparts Contact Rheingold, Giuffra, Ruffo & Plotkin LLP for a free consultation.